Search clinical trials for: Tiotropium (Spiriva®)

Total 14157 results

Teva Branded Pharmaceutical Products R&D, Inc.

Completed

To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

COPD

Germany
Boehringer Ingelheim

Terminated

Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug (NIS PIRATE)

Pulmonary Disease, Chronic Obstructive

Switzerland
Orion Corporation, Orion Pharma

Completed

Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHaler (TIOPIF)

Healthy Volunteer | COPD

Estonia
Boehringer Ingelheim

Completed

Early Intervention Efficacy in COPD

Pulmonary Disease, Chronic Obstructive

Japan
Mylan Inc.
Theravance Biopharma

Completed

Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD

Chronic Obstructive Pulmonary Disease, COPD | Low Peak Inspiratory Flow Rate (PIFR)

United States
3M
Quotient Clinical

Completed

Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Two Reference Products

Healthy

United Kingdom
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Duke University

Withdrawn

Tiotropium Handihaler vs. Tiotropium Respimat in COPD

Chronic Obstructive Pulmonary Disease (COPD)
Irmandade Santa Casa de Misericórdia de Porto Alegre
Novartis

Completed

Indacaterol Versus Tiotropium on Dynamic Hyperinflation in COPD

Chronic Obstructive Pulmonary Disease

Brazil
Boehringer Ingelheim

Completed

Spiriva® Assessment of FEV1 (SAFE)

Pulmonary Disease, Chronic Obstructive

Canada
GlaxoSmithKline

Completed

Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Terminated

Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Austria, Belgium, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, Slovakia, Sweden
Novartis Pharmaceuticals

Completed

Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients (INHALATOR)

Chronic Obstructive Pulmonary Disease (COPD)

Brazil
Radboud University Medical Center

Completed

Interaction in Chronic Obstructive Pulmonary Disease Experiment (ICE)

Smoking | Cardiovascular Disease | Chronic Obstructive Pulmonary Disease | Bronchodilation

Netherlands
Chiesi Farmaceutici S.p.A.

Completed

A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease (GLIMMER)

Chronic Obstructive Pulmonary Disease | COPD

United States
Boehringer Ingelheim

Completed

Preference Tiotropium Respimat Study in COPD

Pulmonary Disease, Chronic Obstructive

Spain
Glenmark Specialty S.A.

Completed

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

United States
Henan University of Traditional Chinese Medicine
Jiangsu Famous Medical Technology Co., Ltd.

Unknown

Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD

Pulmonary Disease, Chronic Obstructive

China
Orion Corporation, Orion Pharma

Completed

Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler (TEMPO)

Healthy Volunteers

Finland
Boehringer Ingelheim

Completed

Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male Volunteers

Healthy
Laval University
Novartis

Completed

Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD (RED)

COPD

Canada
Pearl Therapeutics, Inc.

Completed

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, New Zealand
Sunovion Respiratory Development Inc.

Completed

Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

Chronic Obstructive Pulmonary Disease

United States, United Kingdom
Boehringer Ingelheim

Completed

Re-usable Respimat® Soft MistTM Inhaler Study

Pulmonary Disease, Chronic Obstructive

Denmark, Netherlands, Finland, Belgium, Germany, Norway
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

Chronic Obstructive Pulmonary Disease

United States, Australia, New Zealand
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease | COPD
3M

Completed

Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Reference

Healthy
Boehringer Ingelheim

Completed

Specific Use-Result of Spiriva Respimat® in Asthmatics

Asthma

Japan
McMaster University
Boehringer Ingelheim

Completed

Study to Evaluate the Effects of Tiotropium Bromide on Chronic Obstructive Pulmonary Disease (COPD) During Exercise

COPD
IRCCS Azienda Ospedaliera Universitaria San Martino...

Completed

Bronchodilator Responsiveness in Obliterative Bronchiolitis (BD-OB)

Obliterative Bronchiolitis

Italy
Phargentis SA

Completed

Bioequivalence Study of Tiotropium Bromide Inhalation Powder

COPD

United States, India, Switzerland
Laval University
Boehringer Ingelheim

Completed

Effects of Tiotropium on Walking Capacity in Patients With COPD

Chronic Obstructive Pulmonary Disease

Canada
Lupin, Inc.

Completed

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

Chronic Obstructive Pulmonary Disease

United States
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Italy, Germany, Hungary
Pearl Therapeutics, Inc.

Completed

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease

United States
National Institute of Respiratory Diseases, Mexico

Completed

Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure (EMERALD2)

COPD

Mexico
3M

Completed

Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With A Reference Product

Healthy

United Kingdom
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca

Completed

The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease (LaCrossE)

Chronic Obstructive Pulmonary Disease

Sweden
The Korean Academy of Tuberculosis and Respiratory...
GlaxoSmithKline

Completed

Clinical Outcomes of Tiotropium Plus Fluticasone Propionate/Salmeterol Compared With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD) in Korea

Chronic Obstructive Pulmonary Disease

Korea, Republic of
Xiromed LLC
Laboratorios Liconsa; Exeltis

Completed

Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD) (ARBORUS)

COPD

United States, India
Boehringer Ingelheim

Completed

12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)

Pulmonary Disease, Chronic Obstructive

Sweden
3M
Simbec Research

Completed

Two-period 21 Day Cross-over Study to Compare the Pharmacokinetics of Tiotropium From Two Inhalers

Healthy

United Kingdom
The First Affiliated Hospital of Guangzhou Medical...
Boehringer Ingelheim; Rundo International Pharmaceutical Research & Development...

Completed

Tiotropium In Early Chronic Obstructive Pulmonary Disease Patients in China (Tie-COPD)

Chronic Obstructive Pulmonary Disease

China
3M
Quotient Clinical

Completed

Cross-over Study in Volunteers to Compare the Pharmacokinetics of Tiotropium Delivered From Test and Reference Products

Healthy

United Kingdom
Mayo Clinic
Pfizer; Boehringer Ingelheim

Completed

Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation

Chronic Obstructive Pulmonary Disease | COPD

United States

3

Subscribe